Reports Q1: 70 Pts In Phase IIa Enable Steady Updates While Pivotal Kicks Off

研报英文原文证据摘录

Reports Q1: 70 Pts In Phase IIa Enable Steady Updates While Pivotal Kicks Off

Biotechnology

Artiva Biotherapeutics

TD SECURITIES (USA) LLC EARNINGS UPDATE

May 11, 2026

Price: $10.89 (05/8/2026) Reports Q1: 70 Pts In Phase IIa Enable Steady

Price Target: NA Updates While Pivotal Kicks Off

BUY (1)

ESG SCORE: 59/100

Tyler Van Buren THE TD COWEN INSIGHT

646 562 1343

Artiva had a strong showing with its initial efficacy data, as AlloNK achieved a 70%+ ACR50 at

tyler.vanburen@tdsecurities.com

6 mo., exceeding the 50% goal and any relevant 2L+ RA comps (10-20%). With $300MM raised,

Sam Rollenhagen Artiva is now positioned to execute on its pivotal development plan in RA (H2 start) and will

212 468 7785 continue to share consistent follow-up from the Phase IIa and IIT (data in H2), which now have

samuel.rollenhagen@tdsecurities.com

over 70 patients treated.

Nicholas Lorusso

646 562 1390 Artiva Makes An Entrance With Its 77% ACR50 At Six Months

nick.lorusso@tdsecurities.com

For its first ever update on clinical efficacy in the autoimmune space, Artiva reported a robust

Greg W. Torres, Ph.D. set data in 21 refractory RA patients treated with AlloNK+rituximab, including 13 that had

646 562 1351

over six months of follow-up across its Phase IIa open-label basket trial and the single-center

gregory.wiessner@tdsecurities.com

IIT. At six months, AlloNK led to an ACR50/mACR50 rate of 77% (54% using ACR50 only), far

Key Data above what real-world data suggests JAKi or rituximab achieve in the same setting (13-19%).

Symbol NASDAQ: ARTV The durability was also impressive, with all ACR50 patients at 6 months maintaining their

Beta: 2.87 response. All individual metrics measuring RA severity as well as efficacy in 11 Sjogren's and 5